PLC Systems Inc. (OTC:PLCSF) announced that it will commence its pivotal U.S. trial for the RenalGuard contrast-induced nephropathy treatment.
CIN is a form of acute renal failure caused by exposure to contrast media agents during image-guided cardiology and radiology procedures.
RenalGuard’s U.S. trials have been stalled for years, which PLC officials attributed to a troubled economy and stalled funding.